Opinion|Videos|January 27, 2025
Tailoring Patient Education and Resources in EGFR-Mutant Advanced NSCLC
Panelists discuss the educational resources provided to patients, with Julia explaining how she tailors patient education on breast cancer based on individual needs and preferences, while Melinda shares the courses, books, and other resources that helped her best educate herself during her cancer journey.
Advertisement
Video content above is prompted by the following:
- What education or resources do you provide to patients with breast cancer upon diagnosis? How do you tailor your approach to patient education based on their needs and preferences.
- Which educational courses, books, and other resources allowed you to best educate yourself?
Advertisement
Related to this article
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.
An analysis of the BENEFIT trial supports isatuximab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care in transplant-ineligible NDMM.
C. Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible framework in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
A patient-reported outcomes analysis from the phase 3 IRAKLIA trial showed higher satisfaction with subcutaneous isatuximab via on-body injector.
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acting on a HER2 Result and Navigating Access to Therapy
2
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5